myNEO

• myNEO (Belgium) is a precision medicine firm with a proprietary AI-enabled discovery platform. They combine functional genomics, machine learning, and advanced neoantigen discovery capabilities to identify and translate novel therapeutic targets into next generation therapies 
• Arcturus Therapeutics (NASDAQ:ARCT) is an mRNA medicines company developing mRNA therapeutics and vaccines, with a pipeline across rare, respiratory and infectious diseases
• By joining forces, myNEO and Arcturus will bring together complementary strengths in AI-enabled target discovery, immunology and mRNA to accelerate discovery, strengthen target identification capabilities, and bring innovative therapies to patients faster
• Van Lanschot Kempen acted as Sole Financial Adviser to myNEO and its reference shareholder Novalis Biotech in the transaction. Building on a longstanding relationship with Arcturus, a publicly listed US biotech, the team played a key role in transaction structuring, helping deliver a successful transatlantic combination and a strong outcome for all stakeholders
• This transaction marks Van Lanschot Kempen’s third cross-border Life Sciences & Healthcare M&A transaction in just three months, reinforcing the franchise’s position as a trusted adviser to innovative European life sciences & healthcare companies

“Van Lanschot Kempen has been instrumental in helping develop and mature the relationship between myNEO and Arcturus since 2024. Their strategic advice, sector expertise and hands-on support throughout the process were critical in bringing this transaction to a successful conclusion. We are excited about the road ahead and look forward to joining forces with Arcturus to build the next chapter together.”
Jan Van den Berghe, Founder at Novalis Biotech, majority shareholder of myNEO

myNEO Therapeutics is a precision medicine platform company that leverages its proprietary AI-enabled target discovery capabilities to identify and prioritize novel disease-relevant antigens and therapeutic targets. The company combines large-scale functional genomics, machine learning, immunology and mRNA expertise to develop differentiated next-generation therapies and unlock new opportunities in precision medicine.

• Sole Financial Adviser to Valerio Therapeutics on the acquisition of Etherna Immunotherapies and Sole Placement Agent in its €40m private placement
• Financial Adviser to Basic Pharma in the sale to SHS Capital
• Lead Manager in the USD 920 million Public Offering by Abivax
• Exclusive Financial Adviser to Valerio Therapeutics in the proposed acquisition of Etherna Immunotherapies
• Joint Bookrunner in the up to EUR 84 million Capital Increase by Valneva
• Joint Bookrunner in the SEK 350 million Capital Increase by Egetis Therapeutics
• Joint Book-Running Manager in the USD 200 million IPO by Agomab Therapeutics
• Sole Global Coordinator and Joint Bookrunner in the €105 million Capital Increase by Transgene
• Co-manager in the USD 110 million financing by Oculis
• Co-Lead Manager in the USD 149 million Public Offering by enGene
• Joint Bookrunner in the SEK 672 million Capital Increase by Hansa BioPharma
• Joint Bookrunner in the USD 345 million Capital Increase by uniQure
• Joint Bookrunner in the SEK 720 million sale of existing shares by BioArctic shareholders
• Co-Manager in the USD 748 million Capital Increase by Abivax
• Joint Bookrunner in the USD 201 million Capital Increase by Pharvaris